Intellia Therapeutics Inc. (NASDAQ: NTLA) Stock News & Analysis
Intellia Therapeutics Inc. (NASDAQ: NTLA) is a healthcare company, listed on the NASDAQ. Alpha Stocks Insight has published 1 article on NTLA since Wednesday, June 17, 2026, most recently "Intellia's Phase 3 CRISPR Therapy Cuts HAE Attacks by 87%, Advancing Regulatory Path" on Wednesday, June 17, 2026. Coverage to date spans Health Care, tracking NTLA's earnings, analyst activity, and material corporate events. New coverage is added each trading day.
NTLA Coverage -- 1 Article
Intellia's Phase 3 CRISPR Therapy Cuts HAE Attacks by 87%, Advancing Regulatory Path
Phase 3 data for Intellia's lonvo-z showed an 87% cut in HAE attacks, reinforcing the regulatory outlook for its one-time CRISPR gene editing therapy.
Important Legal Disclaimer
This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.
Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.